Dopa-responsive dystonia: Long-term treatment response and prognosis

Neurology

Volumn 41, Issue 2, 1991, Pages 174-181

  Nygaard, Torbjoern G ^a   Marsden, C David ^b   Fahn, Stanley ^a  

^a Department of Orthopaedic Surgery   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE MESILATE; CARBAMAZEPINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; HALOPERIDOL; LEVODOPA; METOCLOPRAMIDE; TIAPRIDE; TRIHEXYPHENIDYL;

ADULT; CHILD; CONFERENCE PAPER; DYSTONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DEPRESSION; DIHYDROXYPHENYLALANINE; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; DYSTONIA; FEMALE; FOLLOW-UP STUDIES; GAIT; HUMAN; INFANT; LONGITUDINAL STUDIES; MALE; MENSTRUATION; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; TRIHEXYPHENIDYL;

EID: 0026021079     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.41.2_part_1.174     Document Type: Article

References (62)

1. Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv Neurol 1988;50:377-384.
2. Fahn S. Clinical variants of idiopathic torsion dystonia. J Neurol Neurosurg Psychiatry 1989;52(suppl):96-100.
3. Gershanik OS, Nygaard TG. Parkinson’s disease beginning before age 40. Adv Neurol 1990;53:251-258.
4. Nygaard TG. Dopa-responsive dystonia: 20 years into the levodopa era. In: Quinn NP, Jenner PG, eds. Disorders of movement—clinical, pharmacological and physiological aspects. London: Academic Press, 1989:323-337.
5. Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: The spectrum of clinical manifestations in a large North American family. Neurology 1990;40:66-69.
6. Nygaard TG, Gardner-Medwin D, Marsden CD. Dopa-responsive dystonia: The spectrum of clinical manifestations in a family. In: Crossman AR, Sambrook MA, eds. Neural mechanisms in disorders of movement. London: John Libbey, 1989:367-370.
7. Ozelius LO, Kramer PL, Moskowitz CB, et al. Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron 1989;2:1427-1434.
8. Kramer PL, de Leon D, Ozelius L, et al. Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34. Ann Neurol 1990;27:114-120.
9. Kwiatkowski DJ, Nygaard TG, Schuback DE, et al. Identification of a highly polymorphic microsatellite VNTR within the arginino- succinate locus: Exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindred. Am J Hum Genet 1991;48:121-128.
10. Corner BD. Dystonia musculorum deformans in siblings: Treated with Artane (trihexyphenidyl). Proc Roy Soc Med 1952;45:451-452.
11. Geller M, Kaplan B, Christoff N. Dystonic symptoms in children: Treatment with carbamazepine. JAMA 1974;229:1755-1757.
12. Schenck E, Kruschke U. Familiare progressive Dystonie mit Tagesschwankungen. Fallbeschreibung. Erfolgreiche Behandlung mit L-dopa. Klin Wochenschr 1975;53:779-780.
13. Allen N, Knopp W. Hereditary parkinsonism-dystonia with sustained control by L-dopa and anticholinergic medication. Adv Neurol 1976;14:201-214.
14. Williams A, Eldridge R, Levine R, Lovenberg W, Paulson G. Low CSF hydrolase cofactor (tetrahydrobiopterin) levels in inherited dystonia. Lancet 1979;2:410-411.
15. Gordon N. Fluctuating dystonia and allied syndromes. Neuropediatrics 1982;13:152-154.
16. Muenter MD, Gomez MR, Gorden H, Sharpless NS. L-Dopa responsive dystonia musculorum deformans with on-off effect [Abstract]. Neurology 1982;32:A112.
17. LeWitt PA, Newman RP, Miller LP, Lovenberg W, Eldridge R. Treatment of dystonia with tetrahydrobiopterin. N Engl J Med 1983;308:157-158.
18. Deonna T. DOPA-sensitive progressive dystonia of childhood with fluctuations of symptoms—Segawa’s syndrome and possible variants. Neuropediatrics 1986;17:81-85.
19. LeWitt PA, Miller LP, Levine PA, et al. Tetrahydrobiopterin in dystonia: Identification of abnormal metabolism and therapeutic trials. Neurology 1986;36:760-764.
20. Nygaard TG, Duvoisin RC. Hereditary dystonia-parkinsonism syndrome of juvenile onset. Neurology 1986;36:1424-1428.
21. Vogel HP. Zum Problem der L-dopa-sensiblen Dystonie. Akt Neurol 1986;13:102-105.
22. Costeff H, Gadoth N, Mendelson L, Harel S, Lavie P. Fluctuating dystonia responsive to levodopa. Arch Dis Child 1987;62:801-804.
23. Fink JK, Barton N, Cohen W, Lovenberg W, Burns RS, Hallett M. Dystonia with marked diurnal variation associated with biopterin deficiency. Neurology 1988;38:707-711.
24. de Yebenes JG, Moskowitz C, Fahn S, Saint-Hilaire MH. Longterm treatment with levodopa in a family with autosomal dominant torsion dystonia. Adv Neurol 1988;50:101-111.
25. Nygaard TG, Waran S, Chutorian AM. Unexplained cerebral palsy: Dopa-responsive dystonia? [Abstract]. Ann Neurol 1989;26:485-486.
26. Segawa M, Nomura Y, Tanaka S, et al. Hereditary progressive dystonia with marked diurnal fluctuation—consideration on its pathophysiology based on the characteristics of clinical and poly- somnographical findings. Adv Neurol 1988;50:367-376.
27. Nygaard TG, Fahn S. Variability of symptoms in idiopathic dystonia [Abstract]. Neurology 1988;38(suppl 1):419.
28. Muller K, Homberg V, Lenard HG. Motor control in childhood onset dopa-responsive dystonia (Segawa syndrome). Neuropediatrics 1989;20:185-191.
29. Marsden CD, Harrison MGH. Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. Brain 1974;97:793-810.
30. Burke RE, Brin MF, Fahn S, Bressman SB, Moskowitz C. Analysis of the clinical course of non-Jewish, autosomal dominant torsion dystonia. Mov Disord 1986;1:163-178.
31. Narabayashi H, Yokochi M, Iizuki R, Nagatsu T. Juvenile parkinsonism. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of clinical neurology, vol 49. Amsterdam: Elsevier Science, 1986:153-165.
32. Martin WE, Resch JA, Baker AB. Juvenile parkinsonism. Arch Neurol 1971;25:494-500.
33. Clough CG, Mendoza M, Yahr MD. A case of sporadic juvenile Parkinson’s disease. Arch Neurol 1981;38:730-731.
34. Gershanik OS, Leist A. Juvenile onset Parkinson’s disease. Adv Neurol 1986;45:213-216.
35. Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord 1987;2:73-91.
36. Horowitz G, Greenberg J. Pallido-pyramidal syndrome treated with levodopa. J Neurol Neurosurg Psychiatry 1975;38:238-240.
37. Naidu S, Wolfson LI, Sharpless NS. Juvenile parkinsonism: A patient with possible primary striatal dysfunction. Ann Neurol 1978;3:453-455.
38. Still CN, Herberg K-P. Long-term levodopa therapy for torsion dystonia. South Med J 1976;69:564-566.
39. Marsden CD, Jenner P. L-Dopa action in Parkinson’s disease. Trends Neurosci 1981;4:148-150.
40. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson’s disease: Central pathophysiological mechanisms, part 1. Ann Neurol 1988;24:366-371.
41. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-860.
42. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson’s disease: Complementary [,8F]fluorodeoxyglucose [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
43. Martin WRW, Stoessl AJ, Palmer M, et al. PET scanning in dystonia. Adv Neurol 1988;50:223-229.
44. Sawle GV, Leenders KL, Brooks DJ, Marsden CD, Frackowiak RSJ. Dopa-responsive dystonia of juvenile onset: Evidence of disease heterogeneity from 18 F-fluorodopa studies [Abstract], Neurology 1990;40(suppl 1):144.
45. Coyle JT, Snyder SH. Antiparkinson drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 1969;166:899-901.
46. Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985;18:35-40.
47. Burke RE, Fahn S, Marsden CD. Torsion dystonia: A doubleblind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986;36:160-164.
48. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983;33:1255-1261.
49. Barros HMT, Braz S, Leite JR. Effect of carbamazepine on dopamine release and reuptake in rat striatal slices. Epilepsia 1986;27:534-537.
50. Olpe H-R, Jones RSG. The action of anticonvulsant drugs on the firing of locus coeruleus neurons: Selective activating effect of carbamazepine. Eur J Pharmacol 1984;83:169-171.
51. Hornykiewicz O, Kish SJ, Becker LE, Farley I, Shannak K. Biochemical evidence for brain neurotransmitter changes in idiopathic torsion dystonia (dystonia musculorum deformans). Adv Neurol 1988;50:157-165.
52. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Rail TW, Murad F, eds. The pharmacological basis of therapies, 7th ed. New York: Macmillan, 1985:387-445.
53. Kumamoto I, Nomoto M, Yoshidome M, Osame M, Igata A. [Five cases of dystonia with marked diurnal fluctuation and special reference to homovanillic acid in CSF]. Rinsho Shinkeigaku 1984;24:697-702.
54. Nomura K, Yamamoto N, Takahashi I, et al. [Bromocriptine and L-dopa therapy: Comparison in a case of hereditary progressive dystonia with marked diurnal fluctuation]. No To Hattatsu 1987;19:244-248.
55. Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988;3:46-60.
56. Shimoyamada Y, Yoshikawa A, Kashii H, Kihira S, Koike M. [Hereditary progressive dystonia—an observation of the catecholamine metabolism during L-dopa therapy in a 9-year-old girl]. No Ho Hattatsu 1986;18:505-509.
57. Fahn S, Marsden CD. The treatment of dystonia. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths, 1987:359-382.
58. Fahn S. Systemic therapy of dystonia. Can J Neurol Sci 1987;14:528-532.
59. Cook DG, Klawans HL. Levodopa during pregnancy. Clin Neuro- pharmacol 1985;8:93-95.
60. Golbe LI. Parkinson’s disease and pregnancy. Neurology 1987;37:1245-1249.
61. Allain H, Bentue-Ferrer D, Milon D, Moran P, Jacquemard F, Defawe G. Pregnancy and parkinsonism: A case report without problem. Clin Neuropharmacol 1989;12:217-219.
62. Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982;247:1589-1591.